問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Tri-Service General Hospital (在職)

Division of Ophthalmology

Division of Ophthalmology

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of Ophthalmology

Linkou Chang Gung Medical Foundation

更新時間：2023-09-19

陳怡豪
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

19Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳怡豪

List

26Cases

2025-03-01 - 2030-02-01

Phase III

Active
A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05)

  • Condition/Disease

    Gastric Cancer 、Gastroesophageal Junction Cancer

  • Test Drug

    Frozen Crystal Injection Frozen Crystal Injection Injection Injection Injection Film-Coated Tablets Injection

Participate Sites
5Sites

Recruiting5Sites

2019-11-01 - 2024-05-13

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2020-12-15 - 2029-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2020-11-01 - 2027-06-30

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2024-01-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-10-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting2Sites

Recruiting6Sites

2022-12-01 - 2024-10-28

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2019-03-06 - 2022-02-28

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting7Sites

Terminated2Sites

2023-12-31 - 2026-03-18

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting8Sites

Terminated1Sites

2024-06-01 - 2030-12-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB